Dr. Michael Polcari, MD
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- Georgetown University School of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 182
Licensed in Alabama since 2015, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: Georgetown University School of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
AL license 34041 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Allervie Health, Professional Corporation (15 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 182
- Services billed
- 23,860
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, omalizumab, 5 mg | 6,240 | 31 |
| Injection of drug or substance under skin or into muscle | 266 | 41 |
| Professional service for multiple injections of allergen | 155 | 37 |
| Established patient office or other outpatient visit, 30-39 minutes | 65 | 45 |
| Administration and interpretation of patient-focused health risk assessment | 48 | 33 |
| New patient office or other outpatient visit, 45-59 minutes | 24 | 24 |
| Established patient office or other outpatient visit, 40-54 minutes | 22 | 19 |
| Test to measure expiratory airflow and volume | 13 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Birmingham, AL | 183 |
| Azelastine Hcl Other prescribers in Birmingham, AL | 176 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Birmingham, AL | 116 |
| Dupixent Pen (dupilumab) Other prescribers in Birmingham, AL | 116 |
| Ipratropium Bromide Other prescribers in Birmingham, AL | 88 |
| Montelukast Sodium Other prescribers in Birmingham, AL | 85 |
| Fluticasone Propionate Other prescribers in Birmingham, AL | 66 |
| Xolair (omalizumab) | 59 |
| Prednisone Other prescribers in Birmingham, AL | 58 |
| Azithromycin Other prescribers in Birmingham, AL | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 217 payments worth $5,285 in total to this clinician.
| Food and Beverage | $5,186 |
|---|---|
| Education | $98.34 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Jul 3, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $98.34 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,500 in research payments for these studies, mostly to the institutions running them.
- Single-patient expanded access protocol for tradipitant in a single patient with gastroparesis
Vanda Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.